Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies - Scorecard - MDSpire

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies

  • By

  • Amelia Rees

  • Raheej Khan

  • Jessy Choi

  • Clare Nash

  • Daniel Hawley

  • Sasa Pockar

  • Shiao Wei Wong

  • Guilia Varnier

  • Vinod Sharma

  • Alice Chieng

  • Jane Ashworth

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Outcomes of Weekly Adalimumab Treatment in Refractory Non-Infectious Pediatric Uveitis: Impact of Serum Drug Concentrations and Anti-Adalimumab Antibodies

At a Glance

CategoryDetail
ConditionPediatric Chronic Non-Infectious Anterior Uveitis (pCAU)
Key MechanismsAdalimumab (ADA) targets and blocks tumor necrosis factor alpha (TNF-α)
Target PopulationChildren with refractory pCAU
Care SettingTertiary specialist pediatric uveitis centers

Key Highlights

  • ADA is the only biologic agent approved for non-infectious uveitis in children.
  • Weekly ADA dosing is considered for patients with persistent disease despite biweekly dosing.
  • 66.7% of patients achieved disease control at 3 months post-escalation.

Guideline-Based Recommendations

Diagnosis

  • Confirmed diagnosis of pCAU is required for treatment escalation.

Management

  • Escalation to weekly ADA is recommended for patients with inadequate disease control on biweekly dosing.

Monitoring & Follow-up

  • Monitor serum ADA levels and anti-adalimumab antibody titres.

Risks

  • Potential development of anti-drug antibodies and adverse events.

Patient & Prescribing Data

15 pediatric patients with refractory pCAU

Patients previously on biweekly ADA for a mean duration of 1404 days before escalation.

Clinical Best Practices

  • Ensure compliance with treatment regimen before considering escalation.
  • Assess concurrent systemic inflammatory conditions in patients.

Related Resources & Content

Original Source(s)

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies

  • by Amelia Rees, Raheej Khan, Jessy Choi, Clare Nash, Daniel Hawley, Sasa Pockar, Shiao Wei Wong, Guilia Varnier, Vinod Sharma, Alice Chieng, Jane Ashworth

  • May 29, 2026

Related Content

Systemic Corticosteroids as an Adjunct Therapy in Pediatric Orbital Cellulitis: A Comprehensive Review and Meta-Analysis

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

Predictors and Outcomes of Subclinical Inflammation in Pediatric Patients with Familial Mediterranean Fever: A Retrospective Cohort Study from a Single Center